Financhill
Sell
37

OCX Quote, Financials, Valuation and Earnings

Last price:
$3.22
Seasonality move :
-2.87%
Day range:
$3.12 - $3.34
52-week range:
$1.92 - $4.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
22.30x
P/B ratio:
5.77x
Volume:
36.7K
Avg. volume:
98.1K
1-year change:
9.56%
Market cap:
$91.8M
Revenue:
$1.9M
EPS (TTM):
-$4.40

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
OCX
OncoCyte
$154.5K -$0.24 -27.97% -77.88% $4.42
APDN
Applied DNA Sciences
$1.3M -$2.50 27.47% -98.87% --
FONR
Fonar
-- -- -- -- --
PRPH
ProPhase Labs
$3.6M -$0.15 -32.58% -48.57% $13.80
VCYT
Veracyte
$121.6M $0.30 14.14% -93.75% $44.50
XWEL
XWELL
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
OCX
OncoCyte
$3.21 $4.42 $91.8M -- $0.00 0% 22.30x
APDN
Applied DNA Sciences
$1.76 -- $1.9M -- $0.00 0% 0.11x
FONR
Fonar
$13.90 -- $88M 12.09x $0.00 0% 0.88x
PRPH
ProPhase Labs
$0.44 $13.80 $10.5M -- $0.00 0% 0.64x
VCYT
Veracyte
$30.12 $44.50 $2.3B 100.40x $0.00 0% 5.25x
XWEL
XWELL
$1.05 -- $5.5M -- $0.00 0% 0.13x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
OCX
OncoCyte
-- -0.770 -- 1.41x
APDN
Applied DNA Sciences
-- 2.186 -- 4.28x
FONR
Fonar
0.03% 2.259 0.07% 10.85x
PRPH
ProPhase Labs
31.06% -3.224 37.21% 1.12x
VCYT
Veracyte
-- 3.509 -- 4.27x
XWEL
XWELL
-- -2.207 -- 1.72x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
OCX
OncoCyte
$595K -$5.4M -581.11% -581.11% -2253.1% -$5.6M
APDN
Applied DNA Sciences
$684.1K -$3M -113.07% -113.07% -247.7% -$3.4M
FONR
Fonar
$9.7M $2.4M 4.95% 4.95% 11.92% $1.5M
PRPH
ProPhase Labs
-$165K -$7.9M -47.22% -59.59% -252.29% -$4.2M
VCYT
Veracyte
$78.8M $6M 2.14% 2.14% 2.9% $20.4M
XWEL
XWELL
$2.1M -$4.6M -71.82% -71.82% -54.82% -$3.8M

OncoCyte vs. Competitors

  • Which has Higher Returns OCX or APDN?

    Applied DNA Sciences has a net margin of -2255.11% compared to OncoCyte's net margin of -220.57%. OncoCyte's return on equity of -581.11% beat Applied DNA Sciences's return on equity of -113.07%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCX
    OncoCyte
    40.04% -$1.93 -$12.3M
    APDN
    Applied DNA Sciences
    57.17% -$28.00 $12.5M
  • What do Analysts Say About OCX or APDN?

    OncoCyte has a consensus price target of $4.42, signalling upside risk potential of 37.59%. On the other hand Applied DNA Sciences has an analysts' consensus of -- which suggests that it could grow by 85127.27%. Given that Applied DNA Sciences has higher upside potential than OncoCyte, analysts believe Applied DNA Sciences is more attractive than OncoCyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCX
    OncoCyte
    1 2 0
    APDN
    Applied DNA Sciences
    0 1 0
  • Is OCX or APDN More Risky?

    OncoCyte has a beta of 0.793, which suggesting that the stock is 20.716% less volatile than S&P 500. In comparison Applied DNA Sciences has a beta of 0.434, suggesting its less volatile than the S&P 500 by 56.617%.

  • Which is a Better Dividend Stock OCX or APDN?

    OncoCyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Applied DNA Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OncoCyte pays -- of its earnings as a dividend. Applied DNA Sciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCX or APDN?

    OncoCyte quarterly revenues are $1.5M, which are larger than Applied DNA Sciences quarterly revenues of $1.2M. OncoCyte's net income of -$33.5M is lower than Applied DNA Sciences's net income of -$2.6M. Notably, OncoCyte's price-to-earnings ratio is -- while Applied DNA Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OncoCyte is 22.30x versus 0.11x for Applied DNA Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCX
    OncoCyte
    22.30x -- $1.5M -$33.5M
    APDN
    Applied DNA Sciences
    0.11x -- $1.2M -$2.6M
  • Which has Higher Returns OCX or FONR?

    Fonar has a net margin of -2255.11% compared to OncoCyte's net margin of 7.87%. OncoCyte's return on equity of -581.11% beat Fonar's return on equity of 4.95%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCX
    OncoCyte
    40.04% -$1.93 -$12.3M
    FONR
    Fonar
    39.03% $0.29 $159M
  • What do Analysts Say About OCX or FONR?

    OncoCyte has a consensus price target of $4.42, signalling upside risk potential of 37.59%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that OncoCyte has higher upside potential than Fonar, analysts believe OncoCyte is more attractive than Fonar.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCX
    OncoCyte
    1 2 0
    FONR
    Fonar
    0 0 0
  • Is OCX or FONR More Risky?

    OncoCyte has a beta of 0.793, which suggesting that the stock is 20.716% less volatile than S&P 500. In comparison Fonar has a beta of 1.274, suggesting its more volatile than the S&P 500 by 27.394%.

  • Which is a Better Dividend Stock OCX or FONR?

    OncoCyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OncoCyte pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCX or FONR?

    OncoCyte quarterly revenues are $1.5M, which are smaller than Fonar quarterly revenues of $25M. OncoCyte's net income of -$33.5M is lower than Fonar's net income of $2M. Notably, OncoCyte's price-to-earnings ratio is -- while Fonar's PE ratio is 12.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OncoCyte is 22.30x versus 0.88x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCX
    OncoCyte
    22.30x -- $1.5M -$33.5M
    FONR
    Fonar
    0.88x 12.09x $25M $2M
  • Which has Higher Returns OCX or PRPH?

    ProPhase Labs has a net margin of -2255.11% compared to OncoCyte's net margin of -209.38%. OncoCyte's return on equity of -581.11% beat ProPhase Labs's return on equity of -59.59%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCX
    OncoCyte
    40.04% -$1.93 -$12.3M
    PRPH
    ProPhase Labs
    -5.25% -$0.35 $55.3M
  • What do Analysts Say About OCX or PRPH?

    OncoCyte has a consensus price target of $4.42, signalling upside risk potential of 37.59%. On the other hand ProPhase Labs has an analysts' consensus of $13.80 which suggests that it could grow by 3036.36%. Given that ProPhase Labs has higher upside potential than OncoCyte, analysts believe ProPhase Labs is more attractive than OncoCyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCX
    OncoCyte
    1 2 0
    PRPH
    ProPhase Labs
    0 0 0
  • Is OCX or PRPH More Risky?

    OncoCyte has a beta of 0.793, which suggesting that the stock is 20.716% less volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.525, suggesting its less volatile than the S&P 500 by 152.456%.

  • Which is a Better Dividend Stock OCX or PRPH?

    OncoCyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OncoCyte pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCX or PRPH?

    OncoCyte quarterly revenues are $1.5M, which are smaller than ProPhase Labs quarterly revenues of $3.1M. OncoCyte's net income of -$33.5M is lower than ProPhase Labs's net income of -$6.6M. Notably, OncoCyte's price-to-earnings ratio is -- while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OncoCyte is 22.30x versus 0.64x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCX
    OncoCyte
    22.30x -- $1.5M -$33.5M
    PRPH
    ProPhase Labs
    0.64x -- $3.1M -$6.6M
  • Which has Higher Returns OCX or VCYT?

    Veracyte has a net margin of -2255.11% compared to OncoCyte's net margin of 4.31%. OncoCyte's return on equity of -581.11% beat Veracyte's return on equity of 2.14%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCX
    OncoCyte
    40.04% -$1.93 -$12.3M
    VCYT
    Veracyte
    66.39% $0.06 $1.2B
  • What do Analysts Say About OCX or VCYT?

    OncoCyte has a consensus price target of $4.42, signalling upside risk potential of 37.59%. On the other hand Veracyte has an analysts' consensus of $44.50 which suggests that it could grow by 47.74%. Given that Veracyte has higher upside potential than OncoCyte, analysts believe Veracyte is more attractive than OncoCyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCX
    OncoCyte
    1 2 0
    VCYT
    Veracyte
    7 2 1
  • Is OCX or VCYT More Risky?

    OncoCyte has a beta of 0.793, which suggesting that the stock is 20.716% less volatile than S&P 500. In comparison Veracyte has a beta of 1.800, suggesting its more volatile than the S&P 500 by 80.007%.

  • Which is a Better Dividend Stock OCX or VCYT?

    OncoCyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OncoCyte pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCX or VCYT?

    OncoCyte quarterly revenues are $1.5M, which are smaller than Veracyte quarterly revenues of $118.6M. OncoCyte's net income of -$33.5M is lower than Veracyte's net income of $5.1M. Notably, OncoCyte's price-to-earnings ratio is -- while Veracyte's PE ratio is 100.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OncoCyte is 22.30x versus 5.25x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCX
    OncoCyte
    22.30x -- $1.5M -$33.5M
    VCYT
    Veracyte
    5.25x 100.40x $118.6M $5.1M
  • Which has Higher Returns OCX or XWEL?

    XWELL has a net margin of -2255.11% compared to OncoCyte's net margin of -56.4%. OncoCyte's return on equity of -581.11% beat XWELL's return on equity of -71.82%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCX
    OncoCyte
    40.04% -$1.93 -$12.3M
    XWEL
    XWELL
    24.38% -$0.99 $14.8M
  • What do Analysts Say About OCX or XWEL?

    OncoCyte has a consensus price target of $4.42, signalling upside risk potential of 37.59%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 566.67%. Given that XWELL has higher upside potential than OncoCyte, analysts believe XWELL is more attractive than OncoCyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCX
    OncoCyte
    1 2 0
    XWEL
    XWELL
    0 0 0
  • Is OCX or XWEL More Risky?

    OncoCyte has a beta of 0.793, which suggesting that the stock is 20.716% less volatile than S&P 500. In comparison XWELL has a beta of 2.555, suggesting its more volatile than the S&P 500 by 155.514%.

  • Which is a Better Dividend Stock OCX or XWEL?

    OncoCyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OncoCyte pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCX or XWEL?

    OncoCyte quarterly revenues are $1.5M, which are smaller than XWELL quarterly revenues of $8.4M. OncoCyte's net income of -$33.5M is lower than XWELL's net income of -$4.8M. Notably, OncoCyte's price-to-earnings ratio is -- while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OncoCyte is 22.30x versus 0.13x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCX
    OncoCyte
    22.30x -- $1.5M -$33.5M
    XWEL
    XWELL
    0.13x -- $8.4M -$4.8M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is JHX Stock a Buy Sell or Hold?
Is JHX Stock a Buy Sell or Hold?

James Hardie Industries (NYSE:JHX) is a manufacturer of outside building…

Why Did Buffett Sell the S&P 500?
Why Did Buffett Sell the S&P 500?

Warren Buffett has always been an advocate of investing in…

Will SoundHound AI Stock Recover?
Will SoundHound AI Stock Recover?

SoundHound AI (NASDAQ:SOUN) is a leading maker of artificial intelligence…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 36x

Sell
46
Is MSFT Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 32x

Sell
41
Is NVDA Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 37x

Alerts

Buy
78
AJINY alert for Mar 29

Ajinomoto [AJINY] is up 99.61% over the past day.

Buy
69
AGX alert for Mar 29

Argan [AGX] is up 19.83% over the past day.

Sell
24
AIR alert for Mar 29

AAR [AIR] is down 16.36% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock